Literature DB >> 25684636

Recent trends in testosterone testing, low testosterone levels, and testosterone treatment among Veterans.

T J Walsh1, M M Shores, A E Fox, K P Moore, C W Forsberg, C E Kinsey, S R Heckbert, S Zeliadt, M L Thompson, N L Smith, A M Matsumoto.   

Abstract

Low serum testosterone (T) is common and increasingly prevalent with increased age. Recent studies report an 'epidemic' of T prescribing and concern about unnecessary T treatment. We investigated the number of men tested for T, the prevalence of low serum T levels, and initiation of T treatment among those with low T levels in men treated at Veterans Affairs (VA) facilities in the Northwest US (VISN 20). We identified male Veterans aged 40-89 years and examined yearly proportions of men tested for T, found to have low T levels (total T < 280 ng/dL, free T < 34 pg/mL, or bioavailable T < 84 ng/dL), and subsequently treated with T from 2002 to 2011. We excluded men who had T treatment in the year prior and men with diagnoses of prostate or breast cancer. Treatment initiation was defined as the first prescription for T within a year following a low T test. From 2002 to 2011, the yearly population of eligible men in VISN 20 increased from 129 247 to 163 572. The proportion of men who had serum T tests increased from 3.2% in 2002 to 5.8% in 2011. Among the tested men, the percentage of men with low T levels increased from 35.0 to 47.3%. However, the proportion of men with low T levels who were given T treatment within a year decreased from 31.0 to 28.0%. Despite large increases in T testing, and detection of men with low T levels, there was a slight decrease in the proportion of men with low T levels who were treated with T. The decrease in T treatment during this time period contrasts with other studies and may be related to higher comorbidity in Veterans and/or VA formulary restrictions on the use of transdermal T formulations.
© 2015 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  Veterans; testosterone; trends

Mesh:

Substances:

Year:  2015        PMID: 25684636      PMCID: PMC7275368          DOI: 10.1111/andr.12014

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  10 in total

1.  Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism.

Authors:  Bradley D Anawalt; James M Hotaling; Thomas J Walsh; Alvin M Matsumoto
Journal:  J Urol       Date:  2012-02-15       Impact factor: 7.450

2.  Identification of late-onset hypogonadism in middle-aged and elderly men.

Authors:  Frederick C W Wu; Abdelouahid Tajar; Jennifer M Beynon; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Gianni Forti; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Steven Boonen; Dirk Vanderschueren; Fernand Labrie; Ilpo T Huhtaniemi
Journal:  N Engl J Med       Date:  2010-06-16       Impact factor: 91.245

3.  Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse.

Authors:  David J Handelsman
Journal:  Med J Aust       Date:  2013-10-21       Impact factor: 7.738

4.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

Review 5.  Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.

Authors:  Shalender Bhasin; Glenn R Cunningham; Frances J Hayes; Alvin M Matsumoto; Peter J Snyder; Ronald S Swerdloff; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2010-06       Impact factor: 5.958

6.  Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study.

Authors:  Andre B Araujo; Amy B O'Donnell; Donald J Brambilla; William B Simpson; Christopher Longcope; Alvin M Matsumoto; John B McKinlay
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

7.  Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011.

Authors:  J Bradley Layton; Dongmei Li; Christoph R Meier; Julie L Sharpless; Til Stürmer; Susan S Jick; M Alan Brookhart
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

8.  Population-based patterns of prescription androgen use, 1976-2008.

Authors:  Susan A Hall; Gayatri Ranganathan; Liane J Tinsley; Jennifer L Lund; Varant Kupelian; Gary A Wittert; Philip W Kantoff; Alvaro Morales; Andre B Araujo
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-02-07       Impact factor: 2.890

9.  Trends in androgen prescribing in the United States, 2001 to 2011.

Authors:  Jacques Baillargeon; Randall J Urban; Kenneth J Ottenbacher; Karen S Pierson; James S Goodwin
Journal:  JAMA Intern Med       Date:  2013-08-12       Impact factor: 21.873

10.  Prevalence of symptomatic androgen deficiency in men.

Authors:  Andre B Araujo; Gretchen R Esche; Varant Kupelian; Amy B O'Donnell; Thomas G Travison; Rachel E Williams; Richard V Clark; John B McKinlay
Journal:  J Clin Endocrinol Metab       Date:  2007-08-14       Impact factor: 5.958

  10 in total
  3 in total

1.  Comparative Safety of Testosterone Dosage Forms.

Authors:  J Bradley Layton; Christoph R Meier; Julie L Sharpless; Til Stürmer; Susan S Jick; M Alan Brookhart
Journal:  JAMA Intern Med       Date:  2015-07       Impact factor: 21.873

2.  Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels.

Authors:  Thomas J Walsh; Molly M Shores; Chloe A Krakauer; Christopher W Forsberg; Alexandra E Fox; Kathryn P Moore; Anna Korpak; Susan R Heckbert; Steven B Zeliadt; Chloe E Kinsey; Mary Lou Thompson; Nicholas L Smith; Alvin M Matsumoto
Journal:  PLoS One       Date:  2018-06-22       Impact factor: 3.240

3.  Secular trends in testosterone- findings from a large state-mandate care provider.

Authors:  Gabriel Chodick; Shdema Epstein; Varda Shalev
Journal:  Reprod Biol Endocrinol       Date:  2020-03-09       Impact factor: 5.211

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.